Skip to main content
Show — Main navigation Hide — Main navigation
  • Home
  • About
    • The Chair
    • Inquiry Team
    • Expert Groups
    • Inquiry Intermediaries
    • Core Participants
    • Legal Representatives
    • Financial Reports
  • Approach
    • Terms of reference
    • List of Issues
    • Statements of approach
    • Inquiry Principles
  • News
    • News
    • Newsletter Archive
  • Reports
    • Compensation Framework Study
    • First Interim Report
    • Second Interim Report
    • The Inquiry Report
  • Publication Day
  • Evidence
    • Evidence
    • Hearings Archive
  • Compensation
  • Support
    • Confidential Psychological Support
    • Interim Payments
    • Support Groups
    • Get in touch
    • Infected Blood Support Schemes
    • Treatment and aftercare
    • Medical Evidence
    • Expenses Guidance
Accessibility Tool
  • Zoom in
  • Zoom out
  • Reset
  • Contrast
  • Accessibility tool
Get in touch

Quick Exit

Dr McIntyre expressed concern that the SNBTS might seek to introduce NANBH surrogate testing without specific funding and agreement from the SHHD.

  • Read more about Dr McIntyre expressed concern that the SNBTS might seek to introduce NANBH surrogate testing without specific funding and agreement from the SHHD.

There was disappointment about a letter published in the Lancet to which all the Scottish Directors were signatories on the subject of anti-HBc and ALT Screening of all donations and that unilateral action had been taken.

  • Read more about There was disappointment about a letter published in the Lancet to which all the Scottish Directors were signatories on the subject of anti-HBc and ALT Screening of all donations and that unilateral action had been taken.

Professor Cash stated that the SNBTS did not wish and currently had no intention of introducing NANBH surrogate testing unilaterally

  • Read more about Professor Cash stated that the SNBTS did not wish and currently had no intention of introducing NANBH surrogate testing unilaterally

Dr Fraser expressed disappointment in a response to Professor Cash, particularly in light of his understanding that it had been agreed at the 10 June 1987 SNBTS Directors' meeting that there was "a need for synchrony with England and Wales."

  • Read more about Dr Fraser expressed disappointment in a response to Professor Cash, particularly in light of his understanding that it had been agreed at the 10 June 1987 SNBTS Directors' meeting that there was "a need for synchrony with England and Wales."

Dr Forrester suggested that the development to state that the donations had been tested for ALT commercial companies, could lead haemophilia clinicians and SNBTS directors to put pressure on the SHHD to agree to the introduction of surrogate screening.

  • Read more about Dr Forrester suggested that the development to state that the donations had been tested for ALT commercial companies, could lead haemophilia clinicians and SNBTS directors to put pressure on the SHHD to agree to the introduction of surrogate screening.

Dr Contreras expressed further concerns in her letter to Dr Rotblat saying that inclusion of ALT testing information on commercial products may lead to these products considered superior against those not ALT tested, while there is no evidence for any difference.

  • Read more about Dr Contreras expressed further concerns in her letter to Dr Rotblat saying that inclusion of ALT testing information on commercial products may lead to these products considered superior against those not ALT tested, while there is no evidence for any difference.

Dr Rotbalt wrote to Dr Contreras that commercial companies were free to make any testing on their donors, including ALT testing.

  • Read more about Dr Rotbalt wrote to Dr Contreras that commercial companies were free to make any testing on their donors, including ALT testing.

Dr Contreras questioned the decision of Medicines Division to include a statement in commercial plasma packaging that products have been tested for ALT. Argued "screening plasma donations for ALT is totally absurd since any hypothetical benefit obtained by excluding donations with high ALT is lost by pooling".

  • Read more about Dr Contreras questioned the decision of Medicines Division to include a statement in commercial plasma packaging that products have been tested for ALT. Argued "screening plasma donations for ALT is totally absurd since any hypothetical benefit obtained by excluding donations with high ALT is lost by pooling".


Dr Harris summarised the views expressed at the meeting of the Advisory Committee on National Blood Transfusion Service that if testing was introduced it should be national; that research on baseline data would be carried out; and that the position would be monitored in the UK and abroad.

  • Read more about Dr Harris summarised the views expressed at the meeting of the Advisory Committee on National Blood Transfusion Service that if testing was introduced it should be national; that research on baseline data would be carried out; and that the position would be monitored in the UK and abroad.

Dr Gunson sent the Council of Europe's Committee of Experts' report on Blood Transfusion and Immunohaematology, to Dr Smithies DHSS).

  • Read more about Dr Gunson sent the Council of Europe's Committee of Experts' report on Blood Transfusion and Immunohaematology, to Dr Smithies DHSS).

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 692
  • Page 693
  • Page 694
  • Page 695
  • Current page 696
  • Page 697
  • Page 698
  • Page 699
  • Page 700
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to

Inquiry

  • Home
  • About
  • Approach
  • Participate
  • News
  • Evidence
  • Support
  • Get in touch

Legal

  • Terms & Conditions
  • Cookies notice
  • Privacy Notice
  • Accessibility tool

Address

Infected Blood Inquiry
5th Floor
Aldwych House
71-91 Aldwych
London
WC2B 4HN
 
Images of individuals on the website are used with the agreement of those featured or are stock images.

Follow us

© Crown copyright. Licensed under the Open Government Licence v3.0 except where otherwise stated.